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In a pioneer study, we showed 10 years ago that enhanced tissue levels of the matrix metalloproteinases (MMPs) MMP-2 and MMP-9
in gastric cancers, as determined by zymography, were related with worse overall survival of the patients. To corroborate these
observations, we now assessed MMP-2 and MMP-9 with new techniques in an expanded group of gastric cancer patients (n¼81)
and included for comparison MMP-7, MMP-8 and the tissue inhibitors of MMPs, TIMP-1 and -2. All MMPs and TIMP-1 were
significantly increased in tumour tissue compared to normal gastric mucosa. Matrix metalloproteinase-7, -8 and -9, and the TIMPs
showed some correlations with the clinicopathologic parameters TNM, WHO and Laure ´n classification, but their levels were not
related with survival. Regardless of the determination method used, that is, enzyme-linked immunosorbent assay or bioactivity assay,
an enhanced tumour MMP-2 level did not show a significant correlation with any of the clinicopathological parameters, but was
confirmed to be an independent prognostic factor in gastric cancer.
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A decade ago, we were the first to report that the levels of matrix
metalloproteinase (MMP)-2 and MMP-9 in human gastric
carcinoma tissues were enhanced and related to the survival of
the patients, using a simple but laborious zymography technique
in a relatively small group of patients (Sier et al, 1996). Matrix
metalloproteinases are believed to play an important role in
carcinogenesis via the degradation and remodelling of tumour
surrounding extracellular matrix, which could explain the
association with survival (Zucker et al, 2000; McCawley and
Matrisian, 2001; Polette et al, 2004). We concluded that measuring
MMPs could have clinical value as indicators for gastric carcinoma
patients who needed adjuvant therapy and that inhibitors of MMPs
might be useful for therapeutic intervention. Several accomplish-
ments have been made since. The prognostic value of MMPs for
gastric carcinoma patients has been confirmed in several other
studies (Allgayer et al, 1998; Zhang et al, 2003), and clinical trials
testing the effect of MMP inhibitors for patients with various types
of cancer were performed, with variable success (Zucker et al,
2000; Bramhall et al, 2002).
In general, MMPs are secreted as inactive pro-enzymes,
activated by proteolytic cleavage, and controlled in their activity
by interaction with inhibitors. Disturbances in these processes
are of eminent importance in tumour invasion and metastasis
(McCawley and Matrisian, 2001; Polette et al, 2004). In the present
more comprehensive study, we extended our MMP analyses in the
same group of patients and compared the results with those
obtained with a new and more recent group of patients.
Furthermore, instead of zymography, which identifies isoforms,
we now used recently established quantitative bioactivity assays
(BIAs) and specific antigen enzyme-linked immunosorbent assays
(ELISAs) for MMP-2 and MMP-9. Moreover, we compared the
prognostic value of MMP-2 and MMP-9 with those of MMP-7 and
MMP-8 and expanded the study by determination of the inhibitors
TIMP-1 and TIMP-2. In addition, because of the increasing age of
the patients and the length of the follow-up, we now used tumour-
associated survival.
PATIENTS, MATERIALS AND METHODS
Patients and study design
Fresh tissue specimens of 81 patients (21 female and 60 male
subjects, mean age 65.9 years, range 35.10–91.33), who underwent
resection for primary gastric adenocarcinoma at the Department of
Oncologic Surgery of the Leiden University Medical Centre, were
collected prospectively. Immediately after resection, fresh samples
from the mid-central, non-necrotic part of the carcinoma and/or
from distant normal mucosa, taken approximately 10cm from the
tumour, were snap frozen and stored at  701C until extraction, to
be used for research purposes. Various clinicopathological data
were evaluated or collected from patient files. All carcinomas were
classified according to the TNM classification (Hermanek and
Sobin, 1992) and localisation and also diameter of the tumour,
differentiation grade, WHO, Borrman, and Laure ´n classification, as
well as the presence of intestinal metaplasia in the normal gastric
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smucosa, as revised by a gastroenterologist (FK) and a pathologist
(JvK). All patients entered the study at operation date, and the
patient’s time experience ended in the event of death or, when still
alive, at the common closing date. The minimal follow-up was 33
months with a decreasing overall survival according to TNM stage,
that is, from TNM I (52.2%, n¼23), to TNM II (26.9%, n¼26), to
TNM III (28%, n¼25), and to TNM IV (0%, n¼7).
Tissue preparation and protein concentration
Homogenisation of tissue specimens and determination of protein
concentrations were performed as described previously (Sier et al,
1996).
Metalloproteinase-2 and -9 activity assays
Quantitative gelatin zymography and BIAs for MMP-2 and MMP-9
were carried out as described before (Sier et al, 1996; Hanemaaijer
et al, 2000). Active and activatable (pro) MMP-2 and MMP-9 were
determined with the BIA in 96-well plates, coated with mono-
specific antibodies to the MMPs, sample/standard incubation
overnight and detection by modified MMP-sensitive pro-urokinase
in combination with peptide substrate S-2444 and measurement of
absorbance change at 405nm over time. Activation of pro-MMPs
was achieved by incubation with p-aminophenyl-mercuric acetate.
Enzyme-linked immunosorbent assay for MMP-2, MMP-7,
MMP-8, MMP-9, TIMP-1 and TIMP-2
Antigen levels of MMP-2 and MMP-9 were determined using
previously described ELISAs (Hanemaaijer et al, 1998). In brief,
the same catching antibodies were used as for the BIAs. Next,
appropriate dilutions of tissue homogenates were incubated
overnight at 41C. Immunodetection of MMP-2 and MMP-9 was
performed directly or indirectly with in-house anti-MMP-2 and
-MMP-9 biotinylated-polyclonal antibodies. Avidin–horseradish
peroxidase and 3,30,5,50 tetramethyl benzidine were used for the
colouration reaction. The respective amounts of MMP-2 and
MMP-9 were calculated from standard curves. The concentrations
of MMP-7, TIMP1 and TIMP-2 antigens were determined using
commercial ELISAs according to the manufacturer’s instructions
(R&D Systems Europe, Abingdon, UK). The amount of MMP-8 was
measured using a previously described ELISA (Bergmann et al,
1989).
Statistical analysis
Differences between normal and tumour values for all parameters
were calculated using the Wilcoxon signed rank test. For the
survival analyses, the clinicopathological parameters were dichoto-
mised as described previously unless indicated elsewhere. Cutoff
points for MMP data were optimised or medians were used.
Univariate and multivariate survival analyses were performed with
the Cox proportional hazards model, using the SPSS Windows
Release 12.0.1. statistical package (2004, SPSS Inc., Chicago, IL,
USA). Multivariate survival analyses were performed using the Cox
proportional hazards method by separately adding the significant
MMP variables to the dichotomised clinicopathological parame-
ters. Overall and tumour-related survival curves were constructed
using the method of Kaplan and Meier including the Log-rank test.
Differences were considered significant when Pp0.05.
RESULTS
Although quantitative zymography is a reliable and sensitive
technique to identify active and latent isoforms of MMP-2 and
MMP-9, it is a laborious assay to perform. Therefore, we compared
the previously obtained zymography data for MMP-2 and MMP-9
with the results from more practicable and sophisticated
immunoassays, that is, BIAs and ELISAs. Table 1 shows an
overview of the correlation coefficients and P-values for the
different assays (samples n¼100). The total zymography data,
which consist of the sum of active and pro-form bands, correlated
significantly with the total BIA and ELISA levels for both MMP-2
(0.312oro0.533, Pp0.003) and even better for MMP-9 (0.558o
ro0.817, Po0.001). The latent pro-forms of MMP-2 and MMP-9,
separately detected by zymography and BIA, also correlated
significantly. No correlation between both assays was found,
however, for active MMP-2 or MMP-9, indicating that the active
isoform as identified by the very sensitive zymography is not
necessarily functionally active in the less-sensitive BIA, probably
through interaction with inhibitors.
The levels of MMP-2 and MMP-9 as detected with the BIAs and
ELISAs in normal mucosa and tumour tissue in the expanded
group of 81 gastric carcinoma patients are shown in Table 2.
Carcinomas contained significantly higher MMP-2 and MMP-9
levels in antigen as well as activity than adjacent normal tissue.
Particularly remarkable is the presence of more active MMP-2, but
not of active MMP-9, in the tumour tissue homogenates. The most
impressive enhancement (420-fold) in carcinomas compared to
normal tissue, however, was noted for MMP-7 (Table 2). Matrix
metalloproteinase-8 and TIMP-1 were also significantly increased,
whereas tumour TIMP-2 levels were found not to be enhanced.
Interestingly, a striking difference was observed in the correlation
between the primary MMP–TIMP interactor antigen levels, that is,
MMP-9 with TIMP-1 (r¼0.358, Po0.0005) and MMP-2 with
TIMP-2 (r¼0.085, NS).
The levels of MMPs and TIMPs were also evaluated for
correlation with all the clinicopathological parameters. Tumour
levels of MMP-2, TIMP-1 and TIMP-2 did not show significant
correlations with any of these parameters. The mean MMP-7 levels
increased stepwise with TNM classification (Figure 1) and were
Table 1 Spearman’s r for three different assays used for the detection of
MMP-2 and MMP-9 in 50 normal/tumour pairs of tissue homogenates from
gastric carcinoma patients
BIA-total BIA-Pro BIA-active ELISA
MMP-2
Zymo
Total 0.312 0.283 0.203 0.533
0.003 0.008 NS o0.001
Pro 0.356 0.325 0.233 0.439
o0.001 0.002 o0.030 0.003
Active  0.010  0.021 0.053 0.481
NS NS NS o0.001
BIA
Total 1 0.982 0.340 0.505
o0.001 0.001 o0.001
MMP-9
Zymo
Total 0.558 0.604 0.100 0.770
o0.001 o0.001 NS o0.001
Pro 0.533 0.569 0.089 0.740
o0.001 o0.001 NS o0.001
Active 0.417 0.462 0.069 0.523
o0.001 o0.001 NS o0.001
BIA
Total 1 0.930 0.538 0.817
o0.001 o0.001 o0.001
Zymo¼zymography, BIA¼bioactivity assay, ELISA¼antigen; MMP¼matrix metal-
loproteinase. The white values/boxes are the correlations between similar entities, for
example, total–total, Pro–Pro, active–active with different techniques or total with
ELISA.
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ssignificantly enhanced in Laure ´n’s intestinal-type carcinomas
compared to diffuse or mixed types (56716 vs 34722, Po0.02).
Matrix metalloproteinase-8 levels were enhanced in Laure ´n’s
intestinal-type tumours (402772 vs 178729ngmg
 1 protein,
Po0.006) and differentiated tumours (393767 vs 163729ngmg
 1
protein, Po0.002) according to the WHO classification. Matrix
metalloproteinase-9 levels showed a similar enhancement for
Laure ´n’s intestinal-type carcinomas (BIA total activity 140 vs
99Umg
 1 protein, Po0.02; ELISA 29 vs 17ngmg
 1 protein,
Po0.01) and differentiated tumours (BIA total activity 133713 vs
104716Umg
 1 protein, NS; ELISA 2873 vs 1773ngmg
 1 pro-
tein, Po0.02). Matrix metalloproteinase-9 total activity showed a
stepwise decrease with TNM classification, which did not reach
significance (I, 145727; II 127718; III, 120720; IV, 1147
28Umg
 1 protein).
For tumour-associated survival analyses, all MMP and TIMP
parameters in tumour homogenates were evaluated for optimal
cutoff points using the log rank test. Significant cutoffs were only
found for the MMP-2 levels by BIA and ELISA (Figures 2A and B).
No significant association for MMP-7, MMP-8, MMP-9, TIMP-1
and TIMP-2 with tumour-associated survival was found according
to stepwise univariate Cox analyses and thus the medians were
used (hazard ratio and 95% confidence interval ranges of the
median levels varied from 0.801 to 1.257 and from 0.445 to 2.307,
respectively). High MMP-2 levels determined by BIA as well as
ELISA were significantly associated with worse survival, but in
multivariate analyses with the clinicopathological parameters, only
the MMP-2 ELISA kept its independent prognostic value (Table 3).
The consistent prognostic relevance of MMP-2 is underlined by
Figure 2B, in which the old group of patients (n¼50) and the more
recent patients group (n¼31) are independently subdivided based
on a low or high MMP-2 antigen content of the carcinoma, using
the same cutoff value. Similar results were obtained with the BIA
data (not shown).
Table 2 Antigen levels (ngmg
 1 protein) of MMP-2, MMP-7, MMP-8
and MMP-9 and of inhibitors TIMP-1 and TIMP-2 in normal mucosa and
carcinoma of 81 patients with gastric cancer
Mucosa Carcinoma P-value
MMP-2
Antigen 4.770.4 17.072.0 p0.001
Total activity
a 81.1723.6 185.7745.5 p0.001
Pro-form
a 78.9723.6 181.1745.3 0.001
Active
a 2.370.5 4.771.1 0.02
MMP-9
Antigen 9.070.9 24.772.3 p0.001
Total activity
a 67.576.0 128.8711.3 p0.001
Pro-form
a 59.975.6 117.1710.1 p0.001
Active
a 7.671.5 9.572.1 NS
MMP-7 2.070.5 47.1712.4 0.002
MMP-8 95712 319747 p0.001
TIMP-1 8.070.8 16.971.3 p0.001
TIMP-2 5.970.2 6.370.4 NS
Mean7s.e.m. Bioactivity assay levels of MMP-2 and MMP-9 are expressed as units
per mg protein.
aAs determined by BIA. MMP¼matrix metalloproteinase;
BIA¼bioactivity assay; TIMP¼tissue inhibitors of MMP.
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Figure 1 Relation between MMP-7 antigen levels and TNM classification
in gastric carcinomas. The mean and median for the subgroups are
indicated by bars on, respectively, the left- and right-hand side of each
column.
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Figure 2 Kaplan–Meier tumour-related overall survival curves for (A)
MMP-2 BIA total activity, (B) MMP-2 ELISA old vs new gastric cancer
patient groups, with the cutoff levels from the Cox analyses.
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sDISCUSSION
The present study corroborates our previous finding of increased
MMP-2 in gastric cancer. The high MMP-2 antigen and activity
levels were significantly associated with worse survival according
to univariate Cox proportional hazards analysis. In the multi-
variate analysis, including a broad selection of clinical parameters,
the MMP-2 antigen level kept its independent prognostic value, but
the significance for the MMP-2 BIA activity level of the carcinomas
was lost. The optimal cutoff point for MMP-2 antigen calculated
for survival prognosis in the old group of patients was similarly
predictive in the new group of patients, indicating the strength of
MMP-2 as a prognostic indicator for gastric carcinoma patients.
The notion that MMP-2 is a valuable indicator of gastric cancer
progression and prognosis is supported by immunohistochemical,
zymography and mRNA studies showing that MMP-2 is associated
with tumour invasion, lymph node metastasis and survival
(Allgayer et al, 1998; Mo ¨nig et al, 2001; Chuanzhong et al, 2002;
Kabashima et al, 2002; Liu et al, 2002a; Elnemr et al, 2003;
Yokoyama et al, 2004; Ji et al, 2005). The value of MMP-2 as an
independent prognostic marker for gastric carcinomas is under-
scored by our observation that MMP-9, MMP-7, MMP-8, TIMP-1
and TIMP-2 have no prognostic relevance.
Matrix metalloproteinase-9 levels were enhanced in some
clinicopathological subgroups of gastric cancer, that is, according
to the Laure ´n classification and for WHO differentiation grade.
The association between MMP-9 and early stages of gastric
carcinoma, as shown before (Torii et al, 1998; Kabashima et al,
2000), was also present in our study. In contrast to our previous
findings, high MMP-9 levels did not show a significant correlation
with survival and also not for the ratio MMP-9/TIMP-1 (data not
shown) as recently suggested (Zhang et al, 2003). One obvious
explanation for the discrepancy with our previous data is the small
number of patients in the study. However, the relatively high
MMP-9 levels in early gastric carcinomas also might affect the
relation between MMP-9 and prognosis, especially in our extended
follow-up study using tumour-related survival.
Matrix metalloproteinase-7, MMP-8, TIMP-1 and TIMP-2 were
included in the present study as comparisons to evaluate the
prognostic strength of MMP-2 and MMP-9. Matrix metalloprotei-
nase-7 was selected because MMP-7 production in various types of
carcinomas has predominantly been found in tumour cells and
because MMP-7 was recently suggested as potential marker for
gastric carcinoma (Liu et al, 2002b). Although enhanced levels
were found in the different carcinoma subgroups, for example,
TNM stage and Laure ´n’s intestinal type, there was no correlation
between high MMP-7 levels and patients survival. This contrasts in
part with several other studies reporting not only a clear asso-
ciation between MMP-7 expression and gastric cancer progression
but also with survival (Liu et al, 2002b; Ajisaka et al, 2004).
Essential differences with our study are, however, that the latter
studies were carried out using immunohistochemistry, focusing on
MMP-7-expressing carcinoma cells at the invasive front, whereas
our ELISA antigen values were derived from representative overall
parts of the tumours. Matrix metalloproteinase-8, like MMP-9,
is mainly present in neutrophils in carcinomas. Therefore, the
expected correlation in presence of MMP-8 and MMP-9 was
confirmed by the high correlation between both antigen levels
(r 0.810, Pp0.001, n¼158), and the similar distribution according
to the different cancer subgroups. The lack of correlation with
survival was, therefore, not surprising in this study, as described
by others before (Yokoyama et al, 2004).
The levels of TIMP-1 were significantly enhanced in cancer
tissue, but the previously found association between TIMP-1 levels
Table 3 Uni- and multivariate Cox’s proportional hazards analyses of MMP-2, determined by ELISA and BIA, and clinicopathological parameters in relation
to the overall tumour-related survival of 81 patients with gastric cancer
Univariate Multivariate
Parameter n HR CI 95% P HR CI 95% P
Gender
Male vs female 60/21 1.384 0.768–2.494 NS 1.767 0.935–3.342 NS
Age
Median (66 years) 40/41 1.313 0.764–2.255 NS 1.467 0.775–2.774 NS
TNM
I 23/81 1 — 1 —
II 26/81 3.133 1.360–7.222 0.007 4.001 1.510–10.60 0.005
III 25/81 3.021 1.305–6.991 0.010 3.557 1.290–9.813 0.014
IV 7/81 7.387 2.495–21.86 0.000 20.416 4.992–83.49 0.000
Laure ´n
Diffuse/mixed vs intestinal 30/50 0.889 0.516–1.531 NS 1.152 0.353–3.756 NS
WHO differentiation
Well vs poor 54/26 1.133 0.650–1.975 NS 1.270 0.370–4.363 NS
Borrmann
I+II vs III+IV 55/24 1.118 0.609–2.053 NS 0.761 0.386–1.502 NS
Localisation
Cardia vs rest 36/45 0.573 0.330–0.993 0.034 0.330 0.159–0.682 0.003
Diameter tumour
o5 vs 45cm 47/34 1.048 0.608–1.808 NS 0.622 0.337–1.149 NS
Eosinophils
Few vs many 56/24 1.035 0.568–1.886 NS 1.743 0.806–3.766 NS
Intestinal metaplasia
Absent vs present 39/42 0.490 0.280–0.858 0.013 0.706 0.379–1.315 NS
Carcinoma
MMP-2 ELISA
o13.4 vs 413.4ngmg
 1 protein 45/31 2.611 1.455–4.686 0.001 2.620 1.249–5.494 0.011
MMP-2 BIA
o80 vs 480Umg
 1 protein 49/23 1.974 1.089–3.577 0.025 1.493 0.655–3.404 NS
HR¼hazard ratio; CI¼confidence interval.
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sin sections or homogenates from gastric cancer tissue with survival
(Joo et al, 2000; Yoshikawa et al, 2001) was not observed in our
group of patients. However, our group contained relatively less
patients with advanced TNM stages, which could account for the
different results compared with these former studies. In contrast to
what was expected from in vitro studies (Koyama, 2004), we did
not find differences between TIMP-2 levels in normal and
cancerous tissue. Also, the levels between different tumour
subgroups did not vary, indicating a rather constitutive expression
of this inhibitor. As TIMP-2 immunohistochemical staining
combined with in situ hybridisation experiments detected the
expression of TIMP-2 in gastric cancer tissue, primarily in
peritumoral stromal cells rather than in malignant cells (Joo
et al, 2000), we conclude that the localisation of TIMP-2 within the
cancerous tissue might be of crucial importance but apparently not
the total amount of the inhibitor. The recently suggested role for
TIMP-2 in the activation of pro-MMP-2 (Itoh et al, 2001),
combined with the different cell types involved in the expression
of MMP-2 and its main inhibitor TIMP-2 in gastric carcinoma,
indicate the importance of local cell–cell and molecule–molecule
interactions in the activation process. This is particularly notice-
able from our finding that there is no correlation between MMP-2
and TIMP-2 levels in the tissue homogenates, where the increase in
MMP-2 outbalances that of TIMP-2, resulting in an increased net
MMP-2 activity in the tumours, an observation which can only be
made by using the BIA. This process was not observed with MMP-
9 and TIMP-1, where a more balanced increase was found in the
tumours.
Although many in vitro studies, animal models and clinical
studies clearly showed that MMPs are indeed involved in a number
of critical steps during tumour growth and invasion, most
synthetic MMP inhibitors, designed as anticancer agents, failed
to improve patients outcome in clinical trials (Zucker et al, 2000),
showing that our understanding of the working mechanisms of
MMPs in tumour biology is still poor. Coincidentally, gastric
cancer appeared to be one of the few cancers for which a
significant survival benefit from therapy with a matrix metallo-
proteinase inhibitor has been described (Bramhall et al, 2002).
Recent studies indicate that proteolytic MMP activity is involved in
the uncovering or release of specific sites from macromolecules in
the extracellular matrix (McCawley and Matrisian, 2001; Polette
et al, 2004), which at least in vitro leads to various biological
activities. Our study shows that an enhanced MMP-2 level is
consistently and more strongly associated with prognosis of gastric
cancer patients than other MMPs or TIMPs. This association might
be caused by the noninvasion-related activities of MMPs, like
cytokine release/activation, which makes MMP-2 in our opinion an
important player in gastric cancer, deserving further investigation.
Finally, differences in the association of the other MMPs and
TIMPs with gastric cancer survival between our study and other
reports, as mentioned above, might be related to differences in
genetic background, that is, Caucasian vs Asian, which is currently
under study.
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